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Objective: To investigate baseline predictors of month 24 best-corrected visual acuity (BCVA) and central
foveal thickness (CFT) in patients with diabetic macular edema (DME) treated monthly with ranibizumab or sham.
Design: Post hoc analysis of DME patients in 2 identical phase 3 studies.
Participants: Patients randomized to ranibizumab (n ¼ 502) or sham (n ¼ 257).
Methods: Multivariate regression on predictors with P < 0.20 in univariate logistic regression using backward
selection to retain predictors with P < 0.05.
Main Outcome Measures: Patient characteristics correlating with month 24 BCVA in Early Treatment Dia-
betic Retinopathy Study letter score 70 (20/40) or 50 (20/100), gain or loss from baseline BCVA of 15, or
CFT 250 mm.
Results: Baseline predictors of BCVA 20/40 in ranibizumab-treated patients were good BCVA, sub-
macular ﬂuid, no cardiovascular disease, no scatter photocoagulation, and male gender, whereas in sham-
treated patients, they were mild increase in CFT, presence of hard exudates in center subﬁeld, and absence
of renal disease. Predictors of improvement in BCVA letter score 15 in ranibizumab-treated patients were poor
BCVA, submacular ﬂuid, young age, and short diabetes duration, and those in sham-treated patients were poor
BCVA, young age, and mild increase in CFT. Predictors of resolution of edema (CFT 250 mm) in ranibizumab-
treated patients were mild foveal thickening and prominent subfoveal ﬂuid, and those in sham-treated patients
were poor BCVA, mild foveal thickening, and statin usage. Month 24 BCVA 20/100 was predicted by poor
baseline BCVA in ranibizumab-treated patients, and by poor baseline BCVA, large intraretinal cystoid spaces,
renal disease, and absence of hypercholesterolemia in sham-treated patients. Loss of BCVA 15 letters was
predicted in sham-treated patients by submacular ﬂuid, intraretinal cystoid spaces, and renal disease.
Conclusions: Patients with DME and submacular ﬂuid, intraretinal cysts, severe thickening, or renal disease
respond poorly when untreated and respond well to ranibizumab treatment. Elimination of submacular ﬂuid,
intraretinal cysts, and severe thickening are important goals of DME treatment, and in patients with renal disease,
treatment should be very aggressive, with a goal of eliminating all macular ﬂuid. Ophthalmology 2015;122:1395-
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vision loss.1 Although multiple propermeability factors are
likely to be involved, vascular endothelial growth factor
(VEGF) plays a critical role in the excessive leakage from
retinal vessels, and neutralization of VEGF by intraocular
injections of ranibizumab leads to substantial reduction in
DME.2,3 This was conﬁrmed in the RISE and RIDE trials,
2 parallel, phase 3, multicenter, double-masked, sham
injectionecontrolled, randomized studies conducted in the
United States and South America.4 Patients received
monthly injections of 0.3 or 0.5 mg ranibizumab or sham
injections for 24 months. Macular laser was allowed at the
discretion of the investigator starting at month 3. At the
24-month primary end point, 39.2%, 42.5%, and 15.2% of
patients in the 0.3-mg, 0.5-mg, and sham groups had an
improvement in best-corrected visual acuity (BCVA) letter 2015 by the American Academy of Ophthalmology.
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/). Published by Elsevier Inc.score of 15 or more. Thus, monthly injections of ranibizu-
mab provided an excellent outcome in a large percentage of
patients with DME, but whereas some patients improve to
near-normal levels, others are left with substantial visual
disability. In this study, we sought to determine why visual
outcomes vary in patients with DME treated with ranibi-
zumab. Unlike other studies of this type, a major advantage
is the presence of a sham-treated control group for com-
parison to identify characteristics of DME patients that
predict a good or poor prognosis in untreated patients,
allowing us to determine how that is changed by ranibizu-
mab treatment. Patients with BCVA of 20/40 or better can
read and drive, whereas those with BCVA worse than 20/40
are restricted in driving and reading. This is the primary goal
in treating patients with DMEdto help them achieve this
high-functioning level of activitydso our ﬁrst questions are,1395http://dx.doi.org/10.1016/j.ophtha.2015.02.036
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in ranibizumab-treated patients? Are there any characteris-
tics that are so important that they predict this outcome even
in the absence of ranibizumab treatment? The second major
goal of treatment in patients with DME is to prevent severe
visual disability. Previously, BCVA of 20/200 or worse was
considered a cutoff for this, but given new criteria for legal
blindness when using Early Treatment Diabetic Retinopathy
Study (ETDRS) charts (available at: www.lighthouse.org/
about-low-vision-blindness/deﬁnition-legal-blindness/), pa-
tients with BCVA of 20/100 or worse were considered to
have a poor visual outcome; they not only cannot read or
drive, they also have difﬁculty performing many simple
tasks of daily life. Another goal of treatment that indicates to
clinicians that they are doing everything possible to maxi-
mize visual outcome not just for 2 years of treatment, but for
the remainder of a patient’s life, is resolution of macular
edema. With time-domain optical coherence tomography
(OCT), central subﬁeld thickness (CST) of 250 mm or less
provides an anatomic cutoff for clinically signiﬁcant mac-
ular edema, and for trials that used time-domain OCT, CST
of 250 mm or more was an eligibility criterion to identify
patients with clinically signiﬁcant macular edema and an
end point to identify patients who had edema resolution
versus those with residual edema. We sought to determine
which baseline characteristics could predict these function-
ally relevant outcome measures.
Methods
Details of the study design andmethods for the RISE andRIDE trials
(ClinicalTrials.gov identiﬁers NCT00473330 and NCT00473382,
respectively) have been reported previously.4 In the 2 trials, 759
patients with DME were randomized 1:1:1 to monthly injections
of 0.3 mg or 0.5 mg ranibizumab or to sham injections. These
trials complied with the Health Insurance Portability and
Accountability Act and adhered to the tenets of the Declaration of
Helsinki. Institutional review board or ethics committee approval
was obtained for each participating institution, and written
informed consent from each subject was obtained.
Study Participants
The inclusion criteria included (1) age 18 years or older; (2) type
1 or 2 diabetes mellitus; (3) DME causing visual loss, with study
eye BCVA measured by ETDRS protocol5 of a letter score
between 73 and 23 (Snellen equivalent, 20/40e20/320); and
(4) macular edema with CST of 275 mm or more measured by
time-domain OCT. Key exclusion criteria were (1) prior vitreo-
retinal surgery, (2) panretinal or macular laser photocoagulation in
the study eye within the previous 3 months, (3) intraocular corti-
costeroids or antiangiogenic drugs within the previous 3 months,
(4) uncontrolled hypertension, (5) uncontrolled diabetes with
glycosylated hemoglobin of more than 12%, and (6) cerebrovas-
cular accident or myocardial infarction within 3 months.
Study Procedures
During the initial visit, it was determined whether patients had a
history of hypertension, hypercholesterolemia or hyperlipidemia,
cardiovascular disease, renal disease, cerebrovascular disease, and
smoking. Baseline blood pressure and glycosylated hemoglobin
were used in this analysis. Baseline and subsequent OCT scans,1396fundus photographs, and ﬂuorescein angiograms were graded at the
University of Wisconsin Fundus Photograph Reading Center.Data Analysis
Analysis was carried out for all randomized patients. Patients were
categorized as having received either monthly ranibizumab
injections (0.5- or 0.3-mg groups combined) or monthly sham in-
jections. Univariate logistic regression was run on the following
outcome variables at month 24 for ranibizumab- and sham-treated
patients: (1) ﬁnal BCVA of 20/40 or better (70 ETDRS letter
score), (2) improvement from baseline ETDRS letter score of 15
or more, (3) ﬁnal BCVA of 20/100 or worse (50 ETDRS letter
score), (4) reduction from baseline ETDRS letter score of 15 or
more, and (5) ﬁnal CST of 250 mm or less. Predictors with a
P value less than 0.2 in the univariate analysis were included in a
multivariate logistic regression model. The ﬁnal multivariate model
was created by applying a backward selection procedure that
retained only those predictors with P < 0.05. The ﬁnal multivariate
logistic model was used to calculate odds ratios (ORs) and their
95% conﬁdence intervals, with a change of 5 letters, 50 mm, and 5
years considered as standard units of change. All data analyses
were performed using SAS software version 9.2 (SAS, Inc,
Cary, NC).Results
Baseline Characteristics of Study Patients
A total of 502 patients in the ranibizumab group and 257 patients in
the sham group were randomized. Patient and study eye character-
istics assessed at baseline were comparable between the 2 groups and
are summarized in Tables 1 and 2 (available at www.aaojournal.org).Predictors of an Excellent Visual Outcome
In ranibizumab-treated patients, ﬁnal BCVA of 20/40 or better
correlated with good baseline BCVA (OR, 1.59; P < 0.0001), sub-
macular ﬂuid at baseline (OR, 2.88; P ¼ 0.0002), and male gender
(OR, 1.85; P ¼ 0.005; Fig 1A). Final BCVA of 20/40 or better was
less likely in patients who had history of cardiovascular disease
(OR, 0.52; P ¼ 0.006) or who had received panretinal
photocoagulation (OR, 0.44; P ¼ 0.0012; Fig 1A). In sham control
patients, ﬁnal BCVA of 20/40 or better correlated with good
BCVA at baseline (OR, 1.81; P < 0.0001), mild foveal thickening
(OR, 0.81; P ¼ 0.0004), and hard exudates within 2 disc areas of
the fovea (OR, 2.54; P ¼ 0.03) and was less likely in patients who
had a history of renal disease (OR, 0.16; P ¼ 0.01; Fig 1B).Predictors of a Large Improvement in Visual Acuity
In ranibizumab-treated patients, improvement from baseline BCVA
letter score of 15 or more correlated with poor baseline BCVA
(OR, 0.73; P < 0.0001), submacular ﬂuid at baseline (OR, 2.43;
P ¼ 0.004), shorter duration of diabetes (OR, 0.89; P ¼ 0.03), and
young age (OR, 0.88; P ¼ 0.02; Fig 2A). In sham-treated control
patients, improvement from baseline BCVA letter score of 15 or
more correlated with poor baseline BCVA (OR, 0.67; P < 0.0001),
mild foveal thickening at baseline (OR, 0.83; P ¼ 0.006; Fig 2B),
and young age (OR, 0.76; P ¼ 0.004).
Figure 1. Graphs showing baseline predictor variables associated with a best-corrected visual acuity (BCVA) of 20/40 or better at month 24 in patients with
diabetic macular edema treated with (A) monthly injections of 0.3 or 0.5 mg ranibizumab or (B) sham injections. aFor every 5 additional BCVA letters at
baseline, a patient was more likely to achieve a BCVA of 20/40 or better at month 24. bFor every 50-mm increase in central foveal thickness (CFT) at
baseline, a patient was less likely to achieve BCVA of 20/40 or better at month 24. Error bars represent logarithmic transformations of 95% conﬁdence
intervals (CIs). OR ¼ odds ratio; D ¼ change; PRP ¼ panretinal photocoagulation.
Sophie et al  Predictors of Response in DMEPredictors of Resolution of Macular Edema
In ranibizumab-treated patients, ﬁnal CFT of 250 mm or less was
predicted by mild foveal thickening at baseline (OR, 0.89;
P ¼ 0.002) and prominent submacular ﬂuid causing large separa-
tion between photoreceptors and retinal pigment epithelium
(OR, 1.20; P ¼ 0.03; Fig 2A). In sham-treated patients, ﬁnal CFT
of 250 mm or less was more likely in patients with mild foveal
thickening at baseline (OR, 0.83; P ¼ 0.0004), those with poor
baseline BCVA (OR, 0.80; P ¼ 0.0006), or those taking statins
(OR, 2.70; P ¼ 0.0009; Fig 2B).
Predictors of a Poor Visual Outcome
In ranibizumab-treated patients, ﬁnal BCVA of 20/100 or worse was
predicted only by poor baseline BCVA (OR, 0.57; P < 0.0001;
Fig 3A). In sham-treated patients, ﬁnal BCVA of 20/100 or worse
correlated with poor baseline BCVA (OR, 0.55; P < 0.0001), renal
disease (OR, 5.38; P ¼ 0.004), and large cystoid spaces in the
macula (>400 mm: OR, 8.30; P ¼ 0.0025; 200e400 mm: OR, 6.96;
95% conﬁdence interval, 1.83e26.52; P ¼ 0.0045; 200 mm: OR,
5.33; 95% conﬁdence interval, 1.31e21.7; P ¼ 0.02; Fig 3B). FinalBCVA of 20/100 or worse was less likely in patients who had a
history of hypercholesterolemia (OR, 0.44; P ¼ 0.02; Fig 3B).
Predictors of a Large Loss in Visual Acuity
Only 13 of 502 ranibizumab-treated patients had a reduction from
baseline BCVA letter score of 15 or more, making the sample size
insufﬁcient for multivariate analysis. In sham-treated patients,
reduction from baseline BCVA letter score of 15 or more was
predicted by cystoid spaces in the macula (OR, 4.26; P ¼ 0.02),
subretinal ﬂuid (OR, 4.29; P¼ 0.002), and renal disease (OR, 3.81;
P ¼ 0.04; Fig 3B).
Discussion
Intraocular injections of a VEGF-neutralizing protein pro-
vide substantial beneﬁt in patients with DME,4,6,7 but
whereas some patients have an excellent visual outcome,
others are left with substantial visual disability. In this
study, we found that submacular ﬂuid at baseline predicted
an excellent visual outcome in patients treated with1397
Figure 2. Graphs showing baseline predictor variables associated with a gain of 15 or more letters from baseline best-corrected visual acuity (BCVA) letter
score or center point thickness (central foveal thickness [CFT]) of 250 mm or less at month 24 in patients with diabetic macular edema treated with (A)
monthly injections of 0.3 or 0.5 mg ranibizumab or (B) sham injections. aFor every 5 additional BCVA letters at baseline, a patient was less likely to gain 15
or more BCVA letters at month 24. bFor every 5 years older at baseline, a patient was less likely to gain 15 or more BCVA letters at month 24. cFor every 5
years longer the duration of diabetes at baseline, a patient was less likely to gain 15 or more BCVA letters at month 24. dFor every 50-mm increase in CFT at
baseline, a patient was less likely to achieve CFT of 250 mm or less at month 24. eFor every 50-mm increase in subretinal thickness at center point at baseline,
a patient was more likely to achieve a CFT of 250 mm or less at month 24. fFor every 50-mm increase in CFT at baseline, a patient was less likely to gain 15 or
more BCVA letters at month 24. gFor every 5 additional BCVA letters at baseline, a patient was less likely to achieve a CFT of 250 mm or less at month 24.
Error bars represent logarithmic transformations of 95% conﬁdence intervals (CIs). OR ¼ odds ratio; D ¼ change.
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the macula, those who had ﬂuid were more than twice as
likely to have ﬁnal vision of 20/40 or better (OR, 2.88),
improvement from baseline BCVA letter score of 15 or
more (OR, 2.43), or both. Conversely, submacular ﬂuid
predicted a poor visual outcome in sham-treated patients
because they were more than 4 times as likely to lose 15
letters or more from baseline (OR, 4.29). Resolution of
macular edema was more likely in patients treated with
ranibizumab who had mild edema at baseline, which is not
surprising, or in patients with extensive subretinal ﬂuid,
which is somewhat surprising and indicates that suppres-
sion of VEGF is very effective at eliminating subretinal
ﬂuid. Taken together, these data indicate that submacular
ﬂuid that remains for any signiﬁcant period has a1398deleterious effect on visual function, but ranibizumab
causes rapid elimination of submacular ﬂuid, substantial
improvement in vision, and an excellent visual outcome.
Similarly, in patients with retinal vein occlusion, sub-
macular ﬂuid is eliminated rapidly by intraocular injections
of ranibizumab.8
Macular cystoid spaces, like subretinal ﬂuid, seem to be
damaging because their presence predicted a reduction in
BCVA letter score of 15 or more from baseline in sham-
treated patients. The likelihood of a poor visual outcome
increased as the size of cystoid spaces in the macula
increased, suggesting that large cystoid spaces are more
disruptive than small ones. This damaging effect of cystoid
spaces is eliminated by monthly injections of ranibizumab;
macular cystoid spaces did not predict a poor visual
Figure 3. Graphs showing baseline predictor variables associated with (A) best-corrected visual acuity (BCVA) of 20/100 or worse at month 24 in patients
with diabetic macular edema (DME) treated with monthly injections of 0.3 or 0.5 mg ranibizumab or (B) BCVA of 20/100 or worse at month 24 or loss from
baseline BCVA letter score of 15 or more in patients with DME treated with sham injections. *Thirteen of 502 ranibizumab-treated patients had a loss in
visual acuity of 15 or more Early Treatment Diabetic Retinopathy Study letters, which was insufﬁcient for multivariate analysis. aFor every 5 additional
BCVA letters at baseline, a patient was less likely to have BCVA of 20/100 or worse at month 24. bReference group is no cysts. Error bars represent
logarithmic transformations of 95% conﬁdence intervals (CIs). OR ¼ odds ratio; D ¼ change.
Sophie et al  Predictors of Response in DMEoutcome in ranibizumab-treated patients. In contrast to
subretinal ﬂuid and macular cystoid spaces, mild macular
edema seems to be well tolerated; its presence predicted a
good visual outcome in sham-treated patients. However,
when there is more than mild edema, the longer it is present,
the greater the threat to vision; in patients with edema
resulting from retinal vein occlusion, rapid resolution of
edema predicted an excellent visual outcome.8 Relatively
good vision despite edema at the outset of treatment may
suggest that the ﬂuid has not been present long and has
not caused permanent damage because patients with good
baseline vision are more likely to have an excellent visual
outcome when treated with ranibizumab or when receiving
sham treatments. This is consistent with the results of a
previous study.9 Conversely, improvement from baseline
BCVA letter score of 15 or more is more likely in patients
with poor baseline BCVA whether treated with
ranibizumab or sham injections, likely because of a ceiling
effect (patients with good BCVA at baseline had lessvision to gain to return to normal vision, making very
large improvements impossible). Compared with older
patients, the macula in young patients may be better able
to tolerate ﬂuid without incurring loss of visual potential;
young age predicted good visual gain in ranibizumab- and
sham-treated patients. Young age also was predictive of
larger visual acuity beneﬁt in a DME treatment trial con-
ducted by the Diabetic Retinopathy Clinical Research
Network.10
The presence of hard exudates within 2 disc areas of the
fovea predicted a good visual outcome in sham-treated
patients. Exudates often occur at the border between
abnormal and more normal retinal capillaries because as
edema ﬂuid is resorbed by relatively normal capillaries,
the concentration of lipoproteins increases, leading to their
precipitation and the formation of exudates. The presence
of adjacent relatively normal capillaries may improve the
efﬁcacy of macular laser, and because macular laser rescue
therapy was used frequently in the sham group,4 this could1399
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with exudates in the sham group. In eyes treated with
monthly injections of ranibizumab, exudates provided no
predictive value, suggesting that whatever beneﬁcial
effect accompanies the presence of exudates, it is not
relevant when there is strong, sustained suppression of
VEGF. Interestingly, in eyes with DME treated with pro
re nata ranibizumab and prompt or deferred laser in the
Diabetic Retinopathy Clinical Research Network study,
those with exudates within 2 disc areas of the fovea
had a better anatomic outcome than those without
exudates.10 Perhaps with the less sustained suppression
of VEGF provided by pro re nata ranibizumab, the small
advantage for which exudates are a biomarker is still
operative.
A novel and somewhat surprising ﬁnding was that in
sham-treated patients, renal disease was associated with a
reduced chance of obtaining a ﬁnal BCVA of 20/40 or
better (OR, 0.16), an almost 4-fold higher chance of
reduction from baseline BCVA letter score of 15 or more
(OR, 3.81), and a 5-fold increased chance of a ﬁnal BCVA
of 20/100 or worse (OR, 5.38). Renal disease results in less
clearance of urea and other toxins from plasma, which may
make plasma more damaging when it leaks into interstitial
spaces in the macula. This effect was not observed in
patients treated with ranibizumab. Thus, several baseline
characteristics, including renal disease, subretinal ﬂuid, and
large macular cystoid spaces, that were associated with
reduced visual outcomes in sham-treated patients had no
negative associations in ranibizumab-treated patients,
suggesting that suppression of VEGF can eliminate the
negative consequences related to these baseline conditions.
However, ranibizumab treatment unmasked an adverse
effect of panretinal photocoagulation (PRP). Ranibizumab-
treated patients who received PRP before or during the trial
were less likely than those who never received PRP to have
a ﬁnal BCVA of 20/40 or better. The reason for this is
uncertain, but PRP is performed in patients who have
proliferative diabetic retinopathy and hence more severe
diabetic retinopathy, and such patients may be more likely
to have ischemic damage or some other type of damage to
the macula that prevents a ﬁnal BCVA of 20/40 or better
even with complete resolution of macular edema. This
interpretation is consistent with the observation in the
Diabetic Retinopathy Clinical Research Network study that
pro re nata ranibizumab-treated eyes with moderate or
severe nonproliferative diabetic retinopathy had larger
visual acuity beneﬁts compared with eyes with proliferative
diabetic retinopathy or prior PRP.10 The beneﬁts of less
severe retinopathy on treatment outcomes also may be
indicated by the observation that ranibizumab-treated
patients with a shorter duration of diabetes had a higher
chance of gaining 15 or more letters of visual acuity
because a shorter duration of diabetes correlates with less
severe diabetic retinopathy. Patients with no history of
cardiovascular disease were more likely to have a ﬁnal
BCVA of 20/40 or better. Patients with cardiovascular
disease are more likely to have hypertension, atheroscle-
rosis, or both, which can exacerbate diabetic retinopathy
and hence worsen outcomes.11,121400Men were more likely than women to have a ﬁnal BCVA
of 20/40 or better. In a similar analysis of patients in the
Results of the Ranibizumab for Edema of the Macula in
Diabetes study, women were more likely than men to have a
poor visual outcome in the univariate analysis, but this was
not signiﬁcant in the multivariate analysis.9 If future studies
conﬁrm a gender-related difference in visual outcome for
DME patients treated with a VEGF-neutralizing protein, this
could suggest an adverse effect of estrogen or other gender-
related hormones that should be investigated because it
could provide new insights into molecular mechanisms
involved in DME.
A limitation of our study is that it identiﬁed baseline
characteristics that are associated with treatment outcomes,
but it provided no information as to the causes of improved
or worsened outcomes. A strength of our study is the ability
to compare associations in sham- versus ranibizumab-
treated patients, which provided useful insights regarding
which baseline characteristics portend a poor outcome in
untreated patients with DME and how that is altered by
treatment with ranibizumab. Another weakness is that our
study focused solely on baseline characteristics and did not
address the effect of differences in response to ranibizumab
treatment or changes in ﬂuorescein angiograms over time. In
a smaller study, changes in ﬂuorescein angiograms and OCT
scans throughout a 2-year treatment period were included in
the analysis, and it was noted that persistent or recurrent
macular edema or foveal atrophy was associated with poor
visual outcomes.9
In summary, sham-treated patients with renal disease,
submacular ﬂuid, or severe cystic edema are likely to have a
poor visual outcome in the absence of treatment but respond
well when administered monthly injections of ranibizumab.
This suggests that aggressive, sustained suppression of
VEGF can overcome these poor prognostic features. It also
suggests that rapid elimination of subretinal and intraretinal
ﬂuid and preventing their recurrence is a fundamental goal
in the treatment of DME.
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